BCL-XL inhibition induces an FGFR4-mediated rescue response in colorectal cancer
Open accessThe DOI matches its Crossref record; 52 of the 53 references it cites were found in a registry or an index; none of the 28 sources its claims cite is checked for support yet.
Abstract
The heterogeneous therapy response observed in colorectal cancer is in part due to cancer stem cells (CSCs) that resist chemotherapeutic insults. The anti-apoptotic protein BCL-XL plays a critical role in protecting CSCs from cell death, where its inhibition with high doses of BH3 mimetics can induce apoptosis. Here, we screen a compound library for synergy with low-dose BCL-XL inhibitor A-1155463 to identify pathways that regulate sensitivity to BCL-XL inhibition and reveal that fibroblast growth factor receptor (FGFR)4 inhibition effectively sensitizes to A-1155463 both in vitro and in vivo. Mechanistically, we identify a rescue response that is activated upon BCL-XL inhibition and leads to rapid FGF2 secretion and subsequent FGFR4-mediated post-translational stabilization of MCL-1. FGFR4 inhibition prevents MCL-1 upregulation and thereby sensitizes CSCs to BCL-XL inhibition. Altogether, our findings suggest a cell transferable induction of a FGF2/FGFR4 rescue response in CRC that is induced upon BCL-XL inhibition and leads to MCL-1 upregulation.
Overview
CoChat Summary
TL;DR
In colorectal cancer models, low-dose BCL-XL inhibition with A-1155463 triggers an FGF2/FGFR4-dependent rescue response that stabilizes MCL-1 and limits apoptosis. FGFR4 inhibition sensitizes CSCs and patient-derived tumor organoids to A-1155463 in vitro and delays tumor outgrowth in vivo.
Key findings
- A screen of 1,402 inhibitors in Co01 spheroids with 5 nM A-1155463 (an EC10 dose giving an average 8% viability decrease) identified 81 hits at Z score ≥2; 15% targeted Aurora kinases, and many targeted RTKs including VEGFR, PDGFR, FGFR, and c-kit. Ki8751, axitinib, nintedanib, and golvatinib validated, but golvatinib was excluded because it did not significantly induce caspase-3 in CSCs; Bliss scores >10 indicated synergy.
- FGFR4 was the highest expressed target in Co01 cells and patient-derived tumor organoids. Selective FGFR4 inhibitors BLU9931 and H3B-6527 potentiated A-1155463-induced cytotoxicity and caspase-3 activation in TOP-GFP-high CSCs, whereas the FGFR1/2/3 inhibitor AZD4547 did not synergize. In vivo, A-1155463 (1 mg/kg) plus H3B-6527 (5 mg/kg) significantly delayed Co01 tumor outgrowth versus vehicle, while single treatments did not deter growth at that time point; 1 mg/kg A-1155463 showed no platelet impact, whereas 5 and 25 mg/kg caused significant platelet loss within 6 h.
- Low-dose A-1155463 induced MCL-1 protein by 4 h without increasing MCL1 mRNA; FGFR4 inhibition or shFGFR4 knockdown prevented this upregulation. A-1155463 induced FGFR4 and ERK phosphorylation but not AKT; conditioned medium transfer induced MCL-1 in HCT116 and SW948 cells, blocked by H3B-6527 or trametinib; FGF2 treatment increased MCL-1, and shFGF2 blocked A-1155463-induced MCL-1. The MCL-1 inhibitor AZD-5991 plus low-dose A-1155463 produced an approximately 50-fold shift in EC50.
- The combinations did not sensitize normal colon organoids or human platelets.
Methods
- Drug screen: Co01 and Co01-BCL-XL spheroids were seeded at 4,000 cells/well, treated with 1,402 inhibitors at 1 µM alone or with 5 nM A-1155463 for 48 h, and viability measured by CellTiter-Blue. Data were Z score normalized; median Z′ factor was 0.73; hits had Z score ≥2 and were excluded if they also affected the BCL-XL-overexpressing line.
- Validation: Co01 spheroids, patient-derived CRC organoids (P6T, P9T, P16T, P24aT), normal colon organoids, and human platelets were treated in dose-response or matrix titrations; synergy used the Bliss independence model with scores >10 considered synergistic. FACS measured activated caspase-3 in TOP-GFP high/low populations; immunoblot, qRT-PCR, shRNA knockdown, and supernatant transfer assessed mechanism. In vivo: NSG mice for platelet toxicity and NOD/SCID mice with subcutaneous Co01 tumors received A-1155463 (1 mg/kg) and/or H3B-6527 (5 mg/kg) intraperitoneally three times weekly for 3 weeks.
- RNA-seq was performed on Co01 cells (GEO: GSE159504); patient-derived organoid expression data were analyzed via the R2 platform (GSE64392).
Limitations
- Stated: the authors cannot rule out FGFR-independent MCL-1 stabilization, such as displacement of BAX/BAK from BCL-XL to MCL-1 leading to stabilization by displacing NOXA or MULE. The in vivo experiment was limited in numbers and did not induce a dramatic reduction in tumor growth rate with combination treatment; more extensive in vivo testing is needed.
- Stated/evident: the screen and validation used standard culture medium containing FGF2, though the authors also observed FGFR4-dependent MCL-1 induction and combination efficacy without exogenous FGF2. In vivo, FGFR4 inhibition alone had variable effects, with some tumors showing increased growth upon H3B-6527 treatment, possibly via stromal or non-tumor-cell effects that need further exploration.
- Evident from the text: FGFR4 inhibition showed significant but not complete prevention of MCL-1 upregulation in supernatant-transfer experiments, suggesting other receptors or factors may contribute; the paper also notes that MCL-1 targeting in the intestine may have detrimental side effects, including compensatory proliferation and carcinogenesis in MCL-1-deficient models.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures













Verification
Claims the paper makes
0 Valid · 0 Not valid · 26 Not checked · 106 Own results and interpretations
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Gene expression analysis and combinations with selective inhibitors revealed that the efficacy of the identified hits resulted from inhibition of fibroblast growth factor receptor (FGFR)4 signaling.”
§ BCL-XL inhibition induces an FGFR4-mediated rescue response in colorectal cancer > INTRODUCTION
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We thus identified a group of receptor tyrosine kinase (RTK) inhibitors that strongly synergize with low-dose A-1155463 to target colon CSCs and patient-derived tumor organoids for apoptosis.”
§ BCL-XL inhibition induces an FGFR4-mediated rescue response in colorectal cancer > INTRODUCTION
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“All four inhibitors showed synergy with A-1155463 over a range of concentrations (Figure 2C).”
§ BCL-XL inhibition induces an FGFR4-mediated rescue response in colorectal cancer > Drug screen identifies compounds that synergize with low-dose BCL-XL inhibition
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“CP-673451 and crenolanib, both of which are specific inhibitors of PDGFR, showed limited efficacy in a titration with A-1155463 (Figures S2B and S2C).”
§ BCL-XL inhibition induces an FGFR4-mediated rescue response in colorectal cancer > Drug screen identifies compounds that synergize with low-dose BCL-XL inhibition
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We validated these inhibitors in a titration on Co01 cells in combination with A-1155463 and found the most consistent and potent efficacy with four of them, namely, Ki8751, axitinib, nintedanib, and golvatinib (Figures 2B and S2A-S2C).”
§ BCL-XL inhibition induces an FGFR4-mediated rescue response in colorectal cancer > Drug screen identifies compounds that synergize with low-dose BCL-XL inhibition
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
67 more claims
Create a free account to see all 132 claims and to verify the 25 references still open.
- It may state two separate claims as one. 48
- Probably not a substantial claim. 18
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
Zhang, J.-H., Chung, T. D. Y., & Oldenburg, K. R. (1999) · SLAS Discovery · doi:10.1177/108705719900400206 · Cited by 6,847
Sato, T., Stange, D. E., Ferrante, M., Vries, R. G. J., van Es, J. H., van den Brink, S., van Houdt, W. J., Pronk, A., van Gorp, J., Siersema, P. D., et al. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.07.050 · Cited by 3,753
Prospective Derivation of a Living Organoid Biobank of Colorectal Cancer Patients
van de Wetering, M., Francies, H. E., Francis, J. M., Bounova, G., Iorio, F., Pronk, A., van Houdt, W., van Gorp, J., Taylor-Weiner, A., Kester, L., et al. (2015) · Cell · doi:10.1016/j.cell.2015.03.053 · Cited by 2,408
Wnt activity defines colon cancer stem cells and is regulated by the microenvironment
Vermeulen, L., De Sousa E Melo, F., van der Heijden, M., Cameron, K., de Jong, J. H., Borovski, T., Tuynman, J. B., Todaro, M., Merz, C., Rodermond, H., et al. (2010) · Nature Cell Biology · doi:10.1038/ncb2048 · Cited by 1,804
Self-citationThe MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models
Kotschy, A., Szlavik, Z., Murray, J., Davidson, J., Maragno, A. L., Le Toumelin-Braizat, G., Chanrion, M., Kelly, G. L., Gong, J.-N., Moujalled, D. M., et al. (2016) · Nature · doi:10.1038/nature19830 · Cited by 1,047
Colon Cancer Stem Cells Dictate Tumor Growth and Resist Cell Death by Production of Interleukin-4
Todaro, M., Alea, M. P., Di Stefano, A. B., Cammareri, P., Vermeulen, L., Iovino, F., Tripodo, C., Russo, A., Gulotta, G., Medema, J. P., et al. (2007) · Cell Stem Cell · doi:10.1016/j.stem.2007.08.001 · Cited by 1,039
Self-citationIntra-tumor heterogeneity from a cancer stem cell perspective
Prasetyanti, P. R., & Medema, J. P. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0600-4 · Cited by 800
Self-citationA distinct role for Lgr5+ stem cells in primary and metastatic colon cancer
de Sousa e Melo, F., Kurtova, A. V., Harnoss, J. M., Kljavin, N., Hoeck, J. D., Hung, J., Anderson, J. E., Storm, E. E., Modrusan, Z., Koeppen, H., et al. (2017) · Nature · doi:10.1038/nature21713 · Cited by 788
Visualization and targeting of LGR5+ human colon cancer stem cells
Shimokawa, M., Ohta, Y., Nishikori, S., Matano, M., Takano, A., Fujii, M., Date, S., Sugimoto, S., Kanai, T., & Sato, T. (2017) · Nature · doi:10.1038/nature22081 · Cited by 728
Colorectal Cancer Stem Cells Are Enriched in Xenogeneic Tumors Following Chemotherapy
Dylla, S. J., Beviglia, L., Park, I.-K., Chartier, C., Raval, J., Ngan, L., Pickell, K., Aguilar, J., Lazetic, S., Smith-Berdan, S., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002428 · Cited by 589
Pretreatment Mitochondrial Priming Correlates with Clinical Response to Cytotoxic Chemotherapy
Chonghaile, T. N., Sarosiek, K. A., Vo, T.-T., Ryan, J. A., Tammareddi, A., Moore, V. D. G., Deng, J., Anderson, K. C., Richardson, P., Tai, Y.-T., et al. (2011) · Science · doi:10.1126/science.1206727 · Cited by 585
Leverson, J. D., Phillips, D. C., Mitten, M. J., Boghaert, E. R., Diaz, D., Tahir, S. K., Belmont, L. D., Nimmer, P., Xiao, Y., Ma, X. M., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa4642 · Cited by 541
SynergyFinder: a web application for analyzing drug combination dose–response matrix data
Ianevski, A., He, L., Aittokallio, T., & Tang, J. (2017) · Bioinformatics · doi:10.1093/bioinformatics/btx162 · Cited by 530
Tron, A. E., Belmonte, M. A., Adam, A., Aquila, B. M., Boise, L. H., Chiarparin, E., Cidado, J., Embrey, K. J., Gangl, E., Gibbons, F. D., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07551-w · Cited by 490
An informatics approach identifying markers of chemosensitivity in human cancer cell lines.
Amundson, S. A., Myers, T. G., Scudiero, D. A., Kitada, S., Reed, J. C., & Fornace, A. J. (2000) · PubMed · Cited by 477
Leverson, J. D., Zhang, H., Chen, J., Tahir, S. K., Phillips, D. C., Xue, J., Nimmer, P., Jin, S., Smith, M., Xiao, Y., et al. (2015) · Cell Death & Disease · doi:10.1038/cddis.2014.561 · Cited by 440
The developing cancer stem-cell model: clinical challenges and opportunities
Vermeulen, L., de Sousa e Melo, F., Richel, D. J., & Medema, J. P. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70257-1 · Cited by 393
Self-citationSchoenwaelder, S. M., Jarman, K. E., Gardiner, E. E., Hua, M., Qiao, J., White, M. J., Josefsson, E. C., Alwis, I., Ono, A., Willcox, A., et al. (2011) · Blood · doi:10.1182/blood-2011-04-347849 · Cited by 351 · cited 1×
“While this would prove beneficial for CRC therapy, the clinical implementation of BCL-XL inhibition is hampered by the observed toxicity to platelets, whose lifespan is determined by BCL-XL expression (Schoenwaelder et al., 2011).”
BackgroundVo, T.-T., Ryan, J., Carrasco, R., Neuberg, D., Rossi, D. J., Stone, R. M., DeAngelo, D. J., Frattini, M. G., & Letai, A. (2012) · Cell · doi:10.1016/j.cell.2012.08.038 · Cited by 348
Integral role of Noxa in p53-mediated apoptotic response
Shibue, T., Takeda, K., Oda, E., Tanaka, H., Murasawa, H., Takaoka, A., Morishita, Y., Akira, S., Taniguchi, T., & Tanaka, N. (2003) · Genes & Development · doi:10.1101/gad.1103603 · Cited by 338
Domina, A. M., Vrana, J. A., Gregory, M. A., Hann, S. R., & Craig, R. W. (2004) · Oncogene · doi:10.1038/sj.onc.1207692 · Cited by 327 · cited 1×
“Our data therefore suggest that the induction of MCL-1 protein upon A1155463 treatment could be mediated by FGFR4-driven ERK signaling (Domina et al., 2004) (Figure 5C).”
BackgroundO'Neill, K. L., Huang, K., Zhang, J., Chen, Y., & Luo, X. (2016) · Genes & Development · doi:10.1101/gad.276725.115 · Cited by 323 · cited 1×
“To assess if this is involved in upregulation of MCL-1, we made use of HCT-116 cells that are devoid of all pro-apoptotic BH3-only proteins (HCT-116 OctaKO), which are highly resistant to BCL-XL inhibition (O’Neill et al., 2016).”
MethodDiscovery of a Potent and Selective BCL-X L Inhibitor with in Vivo Activity
Tao, Z.-F., Hasvold, L., Wang, L., Wang, X., Petros, A. M., Park, C. H., Boghaert, E. R., Catron, N. D., Chen, J., Colman, P. M., et al. (2014) · ACS Medicinal Chemistry Letters · doi:10.1021/ml5001867 · Cited by 309
Cancer heterogeneity—a multifaceted view
Melo, F. D. S. E., Vermeulen, L., Fessler, E., & Medema, J. P. (2013) · EMBO reports · doi:10.1038/embor.2013.92 · Cited by 287
Self-citationStark, K. L., McMahon, J. A., & McMahon, R. P. (1991) · Development · doi:10.1242/dev.113.2.641 · Cited by 228
PUMA Regulates Intestinal Progenitor Cell Radiosensitivity and Gastrointestinal Syndrome
Qiu, W., Carson-Walter, E. B., Liu, H., Epperly, M., Greenberger, J. S., Zambetti, G. P., Zhang, L., & Yu, J. (2008) · Cell Stem Cell · doi:10.1016/j.stem.2008.03.009 · Cited by 223
Self-citationCammareri, P., Scopelliti, A., Todaro, M., Eterno, V., Francescangeli, F., Moyer, M. P., Agrusa, A., Dieli, F., Zeuner, A., & Stassi, G. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3953 · Cited by 159
Self-citationThe rise of apoptosis: targeting apoptosis in hematologic malignancies
Valentin, R., Grabow, S., & Davids, M. S. (2018) · Blood · doi:10.1182/blood-2018-02-791350 · Cited by 159
Soderquist, R. S., Crawford, L. A., Liu, E., Lu, M., Agarwal, A., Anderson, G. R., Lin, K., Winter, P. S., Çakır, M., & Wood, K. C. (2018) · Nature Communications · doi:10.1038/s41467-018-05815-z · Cited by 141
FGF-2 enhances intestinal stem cell survival and its expression is induced after radiation injury
Houchen, C. W., George, R. J., Sturmoski, M. A., & Cohn, S. M. (1999) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.1999.276.1.g249 · Cited by 136
BCL-2 family deregulation in colorectal cancer: potential for BH3 mimetics in therapy
Ramesh, P., & Medema, J. P. (2020) · Apoptosis · doi:10.1007/s10495-020-01601-9 · Cited by 127
Self-citationWeiss, A., Adler, F., Buhles, A., Stamm, C., Fairhurst, R. A., Kiffe, M., Sterker, D., Centeleghe, M., Wartmann, M., Kinyamu-Akunda, J., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-1291 · Cited by 117
Decreased mitochondrial priming determines chemoresistance of colon cancer stem cells
Colak, S., Zimberlin, C. D., Fessler, E., Hogdal, L., Prasetyanti, P. R., Grandela, C. M., Letai, A., & Medema, J. P. (2014) · Cell Death & Differentiation · doi:10.1038/cdd.2014.37 · Cited by 114
Self-citationCancer stem cell dynamics in tumor progression and metastasis: is the microenvironment to blame?
Fessler, E., Dijkgraaf, F. E., De Sousa E Melo, F., & Medema, J. P. (2013) · Cancer Letters · doi:10.1016/j.canlet.2012.10.015 · Cited by 113
Self-citationFGFR4 promotes stroma-induced epithelial-to-mesenchymal transition in colorectal cancer.
Liu, R., Li, J., Xie, K., Zhang, T., Lei, Y., Chen, Y., Zhang, L., Huang, K., Wang, K., Wu, H., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4718 · Cited by 104
Self-citationTurkington, R. C., Longley, D. B., Allen, W. L., Stevenson, L., McLaughlin, K., Dunne, P. D., Blayney, J. K., Salto-Tellez, M., Van Schaeybroeck, S., & Johnston, P. G. (2014) · Cell Death & Disease · doi:10.1038/cddis.2014.10 · Cited by 98
Weeden, C. E., Ah-Cann, C., Holik, A. Z., Pasquet, J., Garnier, J.-M., Mérino, D., Lessène, G., & Asselin-Labat, M.-L. (2018) · Oncogene · doi:10.1038/s41388-018-0268-2 · Cited by 97
Berger, S., Procko, E., Margineantu, D., Lee, E. F., Shen, B. W., Zelter, A., Silva, D.-A., Chawla, K., Herold, M. J., Garnier, J.-M., et al. (2016) · eLife · doi:10.7554/elife.20352 · Cited by 91
Greaves, G., Milani, M., Butterworth, M., Carter, R. J., Byrne, D. P., Eyers, P. A., Luo, X., Cohen, G. M., & Varadarajan, S. (2018) · Cell Death and Differentiation · doi:10.1038/s41418-018-0183-7 · Cited by 78
Bcl-2 is a critical mediator of intestinal transformation
van der Heijden, M., Zimberlin, C. D., Nicholson, A. M., Colak, S., Kemp, R., Meijer, S. L., Medema, J. P., Greten, F. R., Jansen, M., Winton, D. J., et al. (2016) · Nature Communications · doi:10.1038/ncomms10916 · Cited by 71
Self-citationBcl-xl as the most promising Bcl-2 family member in targeted treatment of chondrosarcoma
de Jong, Y., Monderer, D., Brandinelli, E., Monchanin, M., van den Akker, B. E., van Oosterwijk, J. G., Blay, J., Dutour, A., & Bovée, J. V. M. G. (2018) · Oncogenesis · doi:10.1038/s41389-018-0084-0 · Cited by 68
Maurer, C. A., Friess, H., Buhler, S. S., Wahl, B. R., Graber, H., Zimmermann, A., & Buchler, M. W. (1998) · Digestive Diseases and Sciences · doi:10.1023/a:1026695025990 · Cited by 67
Zhang, H., Xue, J., Hessler, P., Tahir, S. K., Chen, J., Jin, S., Souers, A. J., Leverson, J. D., & Lam, L. T. (2015) · Molecular Cancer · doi:10.1186/s12943-015-0397-y · Cited by 54
BCL-XL is crucial for progression through the adenoma-to-carcinoma sequence of colorectal cancer
Ramesh, P., Lannagan, T. R. M., Jackstadt, R., Atencia Taboada, L., Lansu, N., Wirapati, P., van Hooff, S. R., Dekker, D., Pritchard, J., Kirov, A. B., et al. (2021) · Cell Death & Differentiation · doi:10.1038/s41418-021-00816-w · Cited by 52 · cited 3×
“This likely results from the fact that normal intestinal epithelial cells are resistant to BCL-XL inhibition (Ramesh et al., 2021; van der Heijden et al., 2016).”
BackgroundResultInfluentialSelf-citationShah, O. J., Lin, X., Li, L., Huang, X., Li, J., Anderson, M. G., Tang, H., Rodriguez, L. E., Warder, S. E., McLoughlin, S. M., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0913615107 · Cited by 52
FGFR4 phosphorylates MST1 to confer breast cancer cells resistance to MST1/2-dependent apoptosis
Turunen, S. P., von Nandelstadh, P., Öhman, T., Gucciardo, E., Seashore-Ludlow, B., Martins, B., Rantanen, V., Li, H., Höpfner, K., Östling, P., et al. (2019) · Cell Death & Differentiation · doi:10.1038/s41418-019-0321-x · Cited by 47
Buikhuisen, J. Y., Gomez Barila, P. M., Torang, A., Dekker, D., de Jong, J. H., Cameron, K., Vitale, S., Stassi, G., van Hooff, S. R., Castro, M. A. A., et al. (2021) · Cancers · doi:10.3390/cancers13040801 · Cited by 33
Self-citationMCL1 is required for maintenance of intestinal homeostasis and prevention of carcinogenesis in mice
Healy, M. E., Boege, Y., Hodder, M. C., Böhm, F., Malehmir, M., Scherr, A.-L., Jetzer, J., Chan, L. K., Parrotta, R., Jacobs, K., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.03.017 · Cited by 33
Human colonic fibroblasts regulate stemness and chemotherapy resistance of colon cancer stem cells
Çolak, S., & Medema, J. P. (2014) · Cell Cycle · doi:10.4161/15384101.2014.973321 · Cited by 22
Self-citationPacker, L., Stehbens, S. J., Bonazzi, V., Gunter, J. H., Ju, R. J., Ward, M. S., Gartside, M. G., Byron, S. A., & Pollock, P. M. (2018) · Molecular Oncology · doi:10.1002/1878-0261.12422 · Cited by 22
Macarulla, T. M., Moreno, V., John, B. V., Morris, J. C., Sawyer, M. B., Yong, W. P., Gutierrez, M. E., Karasic, T. B., Sangro, B., Sheng-Shun, Y., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.4095 · Cited by 15
Cited by
The BCL2 family: from apoptosis mechanisms to new advances in targeted therapy
Vogler, M., Braun, Y., Smith, V. M., Westhoff, M.-A., Pereira, R. S., Pieper, N. M., Anders, M., Callens, M., Vervliet, T., Abbas, M., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02176-0 · Cited by 462
Lakhani, N. J., Rasco, D. W., Wang, H., Men, L., Liang, E., Fu, T., Collins, M. C., Min, P., Yin, Y., Davids, M. S., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-1525 · Cited by 30
Chiou, J., Wu, Y., Lee, Y., & Chang, L. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115738 · Cited by 24
Yao, W., Bai, L., Wang, S., Zhai, Y., & Sun, S. (2022) · Neoplasia · doi:10.1016/j.neo.2022.100798 · Cited by 20
Gut aging: A wane from the normal to repercussion and gerotherapeutic strategies
Abankwah, J. K., Wang, Y., Wang, J., Enechojo, O. S., Pozzo, L. D., Chu, X., & Bian, Y. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e37883 · Cited by 19
Metadata
- Authors
- Ramesh, P., Di Franco, S., Atencia Taboada, L., Zhang, L., Nicotra, A., Stassi, G., & Medema, J. P.
- Affiliations
- Oncode Institute (NL)
- University of Palermo (IT)
- Corresponding author
- Medema, Jan Paul
- Venue
- Cell Reports
- Publisher
- Elsevier BV
- Published
- 2022-02
- Volume
- 38
- Issue
- 7
- Pages
- 110374
- ISSN
- 2211-1247 (ISSN-L)
- OpenAlex
- W4213342009
- Cited by
- 26
- References
- 53
- Citations by year
- 2026: 7 · 2025: 8 · 2024: 2 · 2023: 7 · 2022: 2
- FWCI
- 1.24
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc-nd
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
- Locations
- Cell Reports (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion, cc-by)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion, other-oa)
- Funders
- University of Nebraska Medical Center
- China Scholarship Council
- Associazione Italiana per la Ricerca sul Cancro (21445, AIRC IG 21445, 5X 1000, AIRC5x1000)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fibroblast Growth Factor Research
- Keywords
- BCL-XL inhibition, colorectal cancer, cancer stem cells, FGFR4, FGF2, BH3 mimetics, drug synergy, apoptosis, chemoresistance
- MeSH terms
- Axitinib, Aged, Animals, Colon, Drug Evaluation, Preclinical, Drug Synergism, Female, Humans, Indoles, Isoquinolines, Male, Middle Aged, Organoids, Neoplastic Stem Cells, Colorectal Neoplasms, Mice, SCID, Mice, Inbred NOD, Cell Death, Cell Line, Tumor, bcl-X Protein, Mice, Receptor, Fibroblast Growth Factor, Type 4, Benzothiazoles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-11-20, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-20 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.